The article reports on the study on flare phenomenon experienced by patients of prostate cancer during the treatment. Topics discussed include laboratory pattern to avoid discontinuation of therapy, cause of flare such as release of prostate-specific antigen (PSA) and aberrant androgen receptor (AR) activation, and survival gains by using docetaxel in the hormone-sensitive metastatic setting during chemotherapy.